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Selective serotonin reuptake inhibitors (SSRIs) have
recently been reported to specifically kill malignant cells
of B-lymphoid origin. However, we found that all cell
lines investigated underwent apoptotic cell death when
exposed to SSRI concentrations exceeding 10 μM, regard-
less of whether the cell lines were derived from B- or T-
lymphoid tumors or other sources. The structure-activity
relationship readily distinguished the pro-apoptotic and
growth-inhibitory effect of SSRIs from their eponymous
action: acetylation of the SSRIs fluvoxamine and paroxet-
ine abrogated the ability of these compounds to inhibit 5-
HT uptake, but did not impair their cytotoxic action.
Based on these data we conclude that (i) SSRIs inhibit
growth of transformed cells, but that (ii) this effect is nei-
ther specific for malignant cells nor specific for any partic-
ular cellular subset. (iii) The pro-apoptotic effect of SSRIs
(at μM concentrations) is unrelated to their principal
pharmacological action, i.e. inhibition of serotonin
uptake (at nM concentrations). SSRIs or improved ver-
sions thereof are therefore unlikely to represent useful
lead compounds for inducing apoptosis in B-cell derived
tumors.
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